vutrisiran sodium: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
vutrisiran sodium: clinical details
Prescribing considerations
- Initiate under a physician experienced in amyloidosis management.
- Correct serum vitamin A below the normal range and assess possible ocular deficiency symptoms before starting.
- Exclude pregnancy before initiation and discuss effective contraception and future pregnancy plans.
- Benefit–risk assessment is required in severe renal impairment, end-stage renal disease or severe hepatic impairment because these groups have not been studied.
- Safety and efficacy are not established in people under 18.
- Be aware that injection-site reactions and raised alanine transaminase or alkaline phosphatase are listed as common adverse reactions.
Contraindications and cautions
- Severe hypersensitivity, including anaphylaxis, to vutrisiran or an excipient.
Monitoring
- Review promptly for reduced night vision, persistent dry eyes or other ocular symptoms; arrange ophthalmological assessment when vitamin A deficiency is suspected.
- For planned conception, monitor serum vitamin A until it has returned to normal after treatment and supplementation are stopped.
- If pregnancy occurs, obtain vitamin A and thyroid-stimulating hormone levels early and arrange close fetal monitoring, particularly in the first trimester.
- Report suspected adverse reactions through the Yellow Card Scheme; the product is under additional monitoring.
Clinical pharmacology
A chemically stabilised, GalNAc-conjugated double-stranded siRNA targeting variant and wild-type TTR messenger RNA. Hepatocyte uptake enables catalytic TTR mRNA degradation, lowering circulating amyloidogenic TTR. It is degraded by nucleases rather than cytochrome P450 enzymes.
Formulation and product differences
- Ready-to-use, single-use pre-filled syringe for subcutaneous injection.
- Clear, colourless-to-yellow solution; do not use if discoloured or containing particles.
- Essentially sodium-free.
- Do not freeze or store above 30°C; it must not be mixed with other medicinal products.
vutrisiran sodium preparations and strengths
Injection
Route: Parenteral
Strengths: 25 mg
vutrisiran sodium interactions
Formal clinical interaction studies have not been performed, but clinically significant medicine interactions are not expected from vutrisiran's metabolic properties.
Vitamin A supplements
Supplementation is usually prescribed because vutrisiran lowers vitamin A; taking more than advised may be harmful, particularly around pregnancy.
Cytochrome P450 inhibitors or inducers
These are not expected to meaningfully alter vutrisiran, and vutrisiran is not expected to cause clinically significant CYP-mediated interactions.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.